Coronavirus: The Latest

It employs nearly one in ten UK workers, but it’s the industry set to suffer the most when England's new tier system comes into force. CEO of UKHospitality, Kate Nicholls tells Theodora Louloudis why limited evidence of infection in pubs and restaurants means the sector has been wrongly singled out, with ‘devastating’ consequences.

Over a year since the first recorded case of Covid-19 in humans, only one antiviral drug is approved for its treatment. The Telegraph’s Global Health Security team speak to Dr Michael Elliot, Vice President of Medical Affairs at Gilead Sciences, the company that manufactures Remdesivir. They discuss how useful it is, whether big pharma is solely driven by profit and the prognosis for severe coronavirus sufferers in the second wave.

After the US recorded its highest daily rise in new cases and hospitalisations, Deputy Editor of The Telegraph’s Global Health Security Team, Anne Gulland joins Theodora Louloudis to discuss the five mammoth challenges the President Elect will be seeking to overcome in his fight against Covid-19. Top of the list? Tackling misinformation.

After the Pfizer vaccine breakthrough, immunologist Dr Al Edwards tells Theodora Louloudis why the hard work isn't over even once a vaccine is approved, why talk of effective immunisation before Christmas is premature and how this particular vaccine could be particularly difficult to distribute.

As Liverpool becomes England’s first city to be offered mass coronavirus testing, The Telegraph’s Health Editor Laura Donnelly tells Theodora Louloudis why the trial could offer a glimpse into the UK’s future, and why its success hinges on public co-operation.